Benitec Biopharma
Hayward, US · Founded 2019 · Delaware corporation
Find your way into Benitec Biopharma
Sign up to see every warm intro you have to Benitec Biopharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Benitec Biopharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines using its ddRNAi platform, which combines RNA interference with gene therapy to silence disease-causing genes through a single administration. It develops therapeutics for chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD).
Founders & leadership


Board
Reported raises · per SEC filings
Form D private placements$40M disclosed across 1 of 2 rounds · 2024–2026
▶$40MraisedApr 2024 · 17 investors · BiotechnologyRule 506(b)
- J. Kevin BuchiDirector
- Peter FrancisDirector
- Edward SmithDirector
- Jerel BanksExecutive Officer, Director
- Megan BostonExecutive Officer, Director
- Offering amount
- $40M
- Amount sold
- $40M
- Sales commissions
- $2.4M
- Placement agents
- Leerink Partners LLC, Citizens JMP Securities, LLC
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
Companies working in the same space as Benitec Biopharma.
In the news
Frequently asked questions
- What does Benitec Biopharma do?
- Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines using its ddRNAi platform, which combines RNA interference with gene therapy to silence disease-causing genes through a single administration. It develops therapeutics for chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD).
- How much funding has Benitec Biopharma raised?
- Benitec Biopharma has disclosed $40M raised across 1 of its 2 known rounds.
- Where is Benitec Biopharma headquartered?
- Benitec Biopharma is headquartered in Hayward, US.




